Introduction
Genomic DNA copy number alterations (CNAs), resulting in the dosage gain of oncogenes and loss of tumor suppressor genes (TSGs), frequently contribute to the development or progression of cancer (Lengauer et al., 1998) . Mapping chromosomal sites of recurrent genomic DNA gains and losses is often the first step in identifying the underlying oncogenes and TSGs, both in human tumors, and increasingly in transgenic mouse models of human cancer (Jackson-Grusby, 2002) .
Comparative genomic hybridization (CGH) (Kallioniemi et al., 1992) was developed to survey CNAs genome-wide in tumors. In CGH, differentially labeled tumor and normal genomic DNA are comparatively hybridized onto normal metaphase chromosomes, thereby providing a cytogenetic representation of tumor CNAs across the genome. CGH has contributed to the mapping and identification of genes involved in tumor development or progression Shayesteh et al., 1999) ; however, its usefulness has been limited by its low (B20 Mb) mapping resolution. Further, the application of CGH to murine tumors is particularly challenging (Lichter et al., 2000) , since murine chromosomes are acrocentric and of similar size, and therefore difficult to individually discern.
Recently, DNA microarray platforms have provided high-resolution alternatives to conventional, chromosome-based CGH . In array CGH, differentially labeled tumor and normal genomic DNA are cohybridized onto a microarray comprising DNA elements with known genomic map positions. Mapping resolution is dictated by the number of arrayed elements, and is typically several orders of magnitude higher than chromosome-based CGH. Microarrays comprising large genomic DNA clones (e.g. phage P1-derived artificial chromosomes, bacterial artificial chromosomes (BACs) or PCR representations of BACs) (Solinas-Toldo et al., 1997; Pinkel et al., 1998) , cDNAs (Pollack et al., 1999) and oligonucleotides (Lucito et al., 2003) have been used to analyse human tumors, and each of these platforms offers distinct potential advantages . The cDNA microarray-based array CGH method that we have developed (Pollack et al., 1999) , for example, utilizes a readily available microarray platform already in widespread use for expression profiling, provides DNA copy number measurements for individual genes and facilitates the comparison of gene copy number and expression (Pollack and Iyer, 2002) .
Increasingly, mouse tumor models are being developed and used to dissect the altered genes and pathways that lead to human cancer (Jackson-Grusby, 2002) . New strategies, including the creation of 'knock-in' and 'floxed' alleles, provide precise temporal and tissuespecific control of oncogene/TSG expression, better modeling human cancer development and progression (Giuriato et al., 2004) . The tumors that arise in such mouse models frequently exhibit recurrent chromosomal imbalances (Giuriato et al., 2004) , indicative of cooperating mutations. Precise mapping of these 'secondary hits' by CGH should speed the identification of the underlying genes. To date, a small number of array CGH studies have been reported, utilizing mouse BAC arrays providing 1-5 Mb mapping resolution (Hodgson et al., 2001; Cai et al., 2002; Hackett et al., 2003; O'Hagan et al., 2003; Chung et al., 2004) . Here, we report the successful adaptation of our cDNA microarray-based CGH method to characterize murine tumors on mouse arrays with submegabase resolution, and the application to a mouse model of Myc-induced lymphoma (Felsher and Bishop, 1999) .
Results

Performance of CGH on mouse cDNA microarrays
We first tested the performance of cDNA microarraybased CGH by analysing genomic DNA from normal C57BL/6J mice. In a 'self-self' comparative hybridization of normal female genomic DNA (Supplementary Figure S1) , red/green fluorescence ratios measured for both autosomal and X-chromosomal genes were tightly distributed around a mean value of 1 (Figure 1a) . In contrast, when we compared normal male (Cy5-labeled; red) and female (Cy3-labeled; green) genomic DNA, the distribution of fluorescence ratios for X-chromosomal genes was shifted (mean 0.71, Figure 1b) , reflecting the single-copy 'loss' of X-chromosomal genes. Using a decision threshold at the point where the distributions of fluorescence ratios for autosomal and X-chromosomal genes crossed (at B1 s.d. apart from their means), we estimate that each array element provided approximately 85% sensitivity (15% false-negatives) and 85% specificity (15% false-positives) for detection of singlecopy deletion. This level of performance, comparable to that reported for CGH on human cDNA microarrays (Pollack et al., 1999) , should enable the mapping of localized regions of single-copy deletion harboring TSGs.
To determine the relevance of the choice of reference mouse strain used for CGH experiments, we performed and FVB/N (Cy3-labeled) female genomic DNA. We identified numerous highly localized CNAs ( Figure 1d ) not present in comparisons between samples of C57BL/ 6J DNA ( Figure 1c ). These CNAs likely represent DNA copy number polymorphisms between mouse strains, as reported recently (Li et al., 2004) . Although our findings support a preference for using strain-matched reference DNA, they also identify the sites of presumptive polymorphism for the correct interpretation of interstrain array CGH experiments.
To further validate the performance of CGH on mouse cDNA microarrays, we assayed a chemically induced murine lymphoma-derived cell line, P388D1, which had been previously characterized by both spectral karyotyping (SKY) and chromosome-based CGH (Coleman et al., 1999) . By array CGH, we detected gains on chromosomes 1-2, 5-6, 8-10, 15 and 17, and losses on chromosomes 2-7, 11, 14, 16 and X (Figure 2 ). These results were consistent with reported conventional CGH findings (Figure 2 , insets), but provided substantially higher-resolution mapping of the boundaries of CNAs (e.g. compare CGH profiles for chromosome 17), important for the identification of candidate genes.
Application to a murine lymphoma model
Having established the performance characteristics of CGH on mouse cDNA microarrays, we next applied the assay to a murine model of lymphoma. Tetracyclineregulated conditional expression of a Myc transgene in murine hematopoietic cell lineages results in the development of primary T-cell lymphoma (Felsher and Bishop, 1999) . Subsequent inactivation of Myc transgene expression leads to tumor regression. However, approximately 20% of lymphomas eventually recur, and these relapses develop in the absence of Myc expression (Karlsson et al., 2003) . Both primary and relapsed tumors exhibit chromosomal alterations, measured by SKY, consistent with the proposed role of Myc in inducing genomic instability (Felsher, 2003) . Further, relapsed tumors display more numerous chromosomal aberrations, indicating that additional genetic changes might functionally compensate for Myc overexpression (Karlsson et al., 2003 Figure 2 Comparison of array CGH and chromosome CGH. Shown is an array CGH profile of CNAs in the chemically induced murine lymphoma-derived cell line, P388D1. Fluorescence ratios are plotted on a log 10 scale, as a moving average of five adjacent genes, according to chromosome position where red and green indicate positive and negative ratios, respectively. Insets illustrate published chromosome-based CGH profiles for selected chromosomes, and provide a summary of recurrent alterations identified by SKY FISH (modified from Coleman et al., 1999) sought to use array CGH to map these CNAs at high resolution. We characterized CNAs by array CGH in 10 cell lines, derived from four Myc-induced primary lymphomas and six Myc-independent recurrences (Supplementary Figure S1 ). Our array CGH results were in general consistent with previous findings from SKY analysis (Karlsson et al., 2003) (Supplementary Table S1 ), but provided considerably higher-resolution information. In primary tumors and more commonly in Myc-independent relapses, we identified a recurrent genomic DNA loss on distal chr 3, and a recurrent DNA amplification more proximally on chr 3, and on distal chr 15 (Figure 3) . The recurrent loss on chr 3 (Figure 3a ) involved chromosome bands 3G3-3H4, syntenic with human chromosome bands 1p31-p22, and 4q23-q25, and the recurrent amplification on chr 3 (Figure 3a ) included bands 3F2.1-3G3, syntenic with human bands 1q21, 1p13-1p21 and 4q23-q25. On chr 15, the recurrent amplification mapped to chromosome bands 15E1/E2-15F3, syntenic with 22q13 and 12q12-13 in humans (Figure 3b) . Although less frequent, we also observed recurrent whole chromosome gains of chr 4, 5 and 11 (Supplementary Figure S1) .
The genes residing within recurrent regions of amplification and deletion represent candidate oncogenes and TSGs, respectively. Further, by profiling gene expression in parallel, using the same microarray platform, we can identify the relevant subset of candidate genes displaying comparably altered expression. Resid- Figure 3 Array CGH identifies recurrent CNAs in Myc-induced murine lymphomas. Shown are array CGH profiles for selected chromosomes harboring recurrent CNAs on (a) chr 3 and (b) chr 15. Fluorescence ratios are plotted on a log 10 scale, as a moving average of five adjacent genes, according to chromosome position where red and green indicate positive and negative ratios, respectively. Selected candidate cancer genes are indicated. The nomenclature for primary tumors (Pri) and Myc-independent recurrences (R) is as described (Karlsson et al., 2003) ; independent recurrences deriving from the same primary are designated R1, R2, etc. For chr 3, 2/4 primaries display gain compared to 4/6 recurrences (P ¼ 0.41, w 2 test), and for chr 15, 2/4 primaries compared to 5/6 recurrences (P ¼ 0.10) ing within the recurrent amplicon peak on chr 3, and displaying comparably elevated expression, Mcl1 (myeloid cell leukemia sequence 1, Bcl-2 related) (Kozopas et al., 1993 ) encodes a prosurvival Bcl-2 family protein (Zhou et al., 1998) (Figure 3a) . Within the chr 15 recurrent amplicon, candidate genes exhibiting elevated expression included Hdac10 (histone deacetylase 10; chr 15E3), Tegt (testis-enhanced gene transcript, a suppressor of apoptosis; chr 15F1) (Xu and Reed, 1998) and Rarg (retinoic acid receptor gamma; chr 15F3) (Figure 3b ). Other candidate oncogenes highly expressed within nonrecurrent amplifications included Nras (neuroblastoma ras oncogene; chr 3F2.2; sample 6816 Pri) and Ccnl1 (cyclin L1; chr 3E1; sample 1232 R3) (Figure 3a) .
Discussion
We report here the successful adaptation of our cDNA microarray-based CGH technique (Pollack et al., 1999) for the routine characterization of DNA copy number changes in murine tumors, using mouse cDNA microarrays providing an average mapping resolution of 109 kb. We demonstrate the performance of our assay in identifying single-copy alterations (modeled by male-female comparison) and reproducing, albeit at substantially higher resolution, alterations identified in lymphoma genomes by SKY and conventional chromosome-based CGH (Coleman et al., 1999; Karlsson et al., 2003) . Our array CGH method provides improved mapping resolution over previously reported mouse BAC array formats (Hackett et al., 2003; O'Hagan et al., 2003; Chung et al., 2004) , and also facilitates the comparison of gene copy number and expression. Long oligonucleotide microarrays, recently used for array CGH analysis of human specimens (Lucito et al., 2003; Barrett et al., 2004) , may also provide a feasible alternative.
In our application of array CGH to a murine model of lymphoma (Karlsson et al., 2003) , we have identified a recurrent loss on chr 3, and recurrent amplifications on chr 3 and 15. Importantly, the boundaries of CNAs are mapped at high, essentially 'gene-by-gene', resolution, permitting identification of candidate genes contributing to the development of primary lymphomas or Myc-independent relapses. Of particular interest, residing within the peak of recurrent amplification on chr 3, and displaying comparably elevated expression, Mcl1 encodes a Bcl-2 family member, which promotes survival in a spectrum of hematopoietic cell types by inhibiting apoptosis (Zhou et al., 1998) . Expression of Mcl1, which selectively inhibits the proapoptotic protein Bim, is essential both in early lymphoid development and later in the maintenance of mature lymphocytes (Opferman et al., 2003) . Consonant with our findings, Mcl1 is frequently overexpressed in human B-cell lymphomas, including Myc-induced Burkitt's lymphomas (Cho-Vega et al., 2004) , and a Burkitt lymphoma subline with MCL1 amplification exhibited enhanced survival on exposure to apoptotic agents (Vrana et al., 2002) . While this and other recurrent CNAs we identified were more commonly observed in Mycindependent recurrences, the sample set is too small to infer their relative contribution in tumor development vs recurrence.
Mice are increasingly used to further our understanding of human tumor development and progression in a genetically tractable model organism (JacksonGrusby, 2002; Giuriato et al., 2004) . Here, we have demonstrated the application of array CGH to a murine model of Myc-induced lymphoma. Newer murine tumor models are also more faithfully representing human epithelial tumors. In particular, in the context of telomerase deficiency, mice develop epithelial tumors with numerous unbalanced chromosome aberrations (Artandi et al., 2000; O'Hagan et al., 2002) , reminiscent of human epithelial tumors. CGH on mouse cDNA microarrays provides a reliable method and powerful approach to interrogate such tumors, and to identify genes relevant to human cancer development and progression.
Materials and methods
Samples
Normal male and female C57BL/6J murine DNA was purchased from the Jackson Laboratory (Bar Harbor, ME, USA). P388D1, a chemically induced murine lymphomaderived cell line (DBA/2), was kindly provided by Dr Siegfried Janz (National Cancer Institute, Bethesda, MD, USA). Lymphoma cell lines established from Myc-induced primary and recurrent lymphomas (FVB/N) have been described (Karlsson et al., 2003) . Genomic DNA and RNA were isolated from cell lines using the TRIZOL (Invitrogen) method.
Array CGH and expression profiling cDNA microarrays were obtained from the Stanford Functional Genomics Facility and included B42 000 murine cDNAs (B49% full-length clones from the RIKEN collection (http://www.gsc. riken.go.jp/e/FANTOM/), B36% from the NIA 15K clone set (http://lgsun.grc.nia.nih.gov/cDNA/ 15k.html), B3% miscellaneous custom-ordered clones, B2.3% from the BMAP (Brain Molecular Anatomy Project; http://trans.nih.gov/bmap/resources/resources.htm) clone set, B2.3% Research Genetics sequence-verified clones (Invitrogen) and the rest from private libraries, together representing approximately B14 000 different mapped genes. Array CGH and expression profiling were performed essentially as described Bullinger et al., 2004) , with modifications as noted. In brief, for array CGH, 4 mg of DpnIIdigested genomic DNA from test samples was random primer labeled with Cy5 and cohybridized to the microarray along with 4 mg of Cy3-labeled DpnII-digested sex-matched normal reference DNA, in the presence of 50 mg murine Cot-1 DNA (Invitrogen) to block hybridization to repetitive murine DNA sequences. For gene expression profiling, 50 mg total RNA from test samples and 50 mg Universal Mouse Reference RNA (Stratagene) were differentially labeled with Cy5 and Cy3, respectively, and cohybridized to cDNA microarrays. Following overnight hybridization and washing, arrays were imaged using a GenePix 4000B scanner (Axon). Fluorescence ratios were extracted using GenePix Pro software, and the data uploaded into the Stanford Microarray Database (Gollub et al., 2003) for storage, retrieval and analysis. The complete microarray data sets are available at http://smd.stanford.edu.
Data analysis
For array CGH, background-subtracted fluorescence ratios were normalized for each array by setting the average fluorescence ratio for all array elements equal to 1. Genes were considered reliably measured if the fluorescence intensity for the Cy3 reference channel was at least 150 U (approximately 1.4-fold) above background. Map positions for arrayed cDNA clones were assigned using the NCBI genome assembly, accessed through the UCSC genome browser (NCBI Build 30). In this way, approximately 23 000 arrayed clones representing 14 000 unique genes could be assigned map positions, providing an average and median mapping resolution of 109 and 22 kb, respectively. DNA copy number gains and losses were identified using the CLuster Along Chromosomes method (CLAC; http://www-stat.stanford.edu/~wp57/CGHMiner) (Wang et al., 2005) . Briefly, the CLAC algorithm builds a hierarchical cluster-style tree along each chromosome, such that neighboring genes with positive and negative ratios are separated into different clusters. Gains and losses are then called significantly based on the height and width of clusters, and a false discovery rate is estimated by comparison to normal-normal hybridization data. When indicated, fluorescence ratios are reported as a moving average of five neighboring genes. For expression profiling, fluorescence ratios were normalized for each array, and then well-measured genes (fluorescence intensities for the Cy5 or Cy3 channel at least twofold above background) were subsequently 'mean-centered' (i.e. reported for each gene relative to the mean ratio across all samples).
Abbreviations CGH, comparative genomic hybridization; CNA, copy number alteration; TSG, tumor suppressor gene.
